| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
|
Medicine details |
|
| Medicine name | canagliflozin (Invokana®) |
| Formulation | 100 mg, 300 mg film-coated tablet |
| Reference number | 859 |
| Indication | In adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control as add-on therapy with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Endocrine system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/12/2013 |
| NICE guidance | TA315: Canagliflozin in combination therapy for treating type 2 diabetes |